Skip to main content

MS news

Our news web pages include ground-breaking multiple sclerosis news and research from around the world. 

These news stories are taken from external sources and as such, MS-UK does not verify, endorse or accept responsibility for their content.

Some of these pages have been written for medical professionals and this can be reflected in the complexity of language and content.

Supporting you

We’re here to support you, whether you are awaiting a diagnosis of multiple sclerosis or have been living with the condition for years. 

Find out more about the MS-UK Helpline

Find out more about our Choices booklets

Find out more about New Pathways magazine

 


A five-year study comparing the efficacy of different treatments for relapsing-remitting multiple sclerosis (RRMS) found that, in general, Lemtrada (alemtuzumab) and Tysabri (natalizumab) are more...
Merck recently presented new efficacy data from its three Phase 3 clinical trials, showing that a relatively short course of treatment with Cladribine tablets led to long-term reductions in...
Sanofi Genzyme presented positive results from its Phase 4 study into patient-reported assessments of Aubagio (teriflunomide), an approved oral treatment for relapsing forms of multiple sclerosis (...
In a large nationwide study in Finland, researchers found evidence supporting the link between vitamin D deficiency and an increased risk for multiple sclerosis in women. The results were given in an...
Preliminary results of a study in Danish patients with multiple sclerosis suggest that inverse comorbidity may exist in the MS population, lowering patients’ risk for other types of diseases. The...
There might be years-long lags in response to disease-modifying drugs in patients with progressive forms of multiple sclerosis, according to a study that analysed data from two large clinical trials ...
Patients with relapsing-remitting multiple sclerosis (RRMS) might benefit from cholecalciferol (vitamin D3) oil as an add-on therapy in the early phases of the disease. This finding was presented in...
Long-term observations together with mathematical modelling present a way of predicting the likely disability trajectory of multiple sclerosis patients. The approach was outlined in a presentation,...
A pilot study exploring the antioxidant lipoic acid in patients with secondary progressive multiple sclerosis (SPMS) has found that treatment for two years reduced the speed of brain tissue loss and...
Children with multiple sclerosis in North America identified a number of challenges in adhering to disease-modifying therapies — a potential first step to devising therapeutic approaches that might ...

Pages